Clinical Trials
5 trialsNCT02345265 2026-05-28
Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03314740 2025-01-10
BAROCCO
Mario Negri Institute for Pharmacological Research
Phase 2 Completed
NCT03117933 2024-01-23
OCTOVA
University of Oxford
Phase 2 Completed
NCT02889900 2022-03-08
CONCERTO
AstraZeneca
Phase 2 Completed
NCT02340611 2018-06-12
A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib
University Health Network, Toronto
Phase 2 Completed